The frequency of CD4 + CD25 + FoxP3 + CD127 − cells in Bet v 1 contiguous overlapping peptide immunotherapy as a putative marker of efficacy

Paweł Gajdanowicz, Dries Van Elst, Sylwia Smolińska, Andrzej Eljaszewicz, Liam O'Mahony, Alexander Kettner, Marek Jutel

Open source

DOI
10.1111/all.14342
Published
2020-05-15
Container
Allergy
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/all.14342,
  title = {The frequency of CD4 + CD25 + FoxP3 + CD127 − cells in Bet v 1 contiguous overlapping peptide immunotherapy as a putative marker of efficacy},
  author = {Paweł Gajdanowicz and Dries Van Elst and Sylwia Smolińska and Andrzej Eljaszewicz and Liam O'Mahony and Alexander Kettner and Marek Jutel},
  year = {2020},
  journal = {Allergy},
  doi = {10.1111/all.14342},
  url = {https://doi.org/10.1111/all.14342}
}

RIS

TY  - JOUR
TI  - The frequency of CD4 + CD25 + FoxP3 + CD127 − cells in Bet v 1 contiguous overlapping peptide immunotherapy as a putative marker of efficacy
AU  - Paweł Gajdanowicz
AU  - Dries Van Elst
AU  - Sylwia Smolińska
AU  - Andrzej Eljaszewicz
AU  - Liam O'Mahony
AU  - Alexander Kettner
AU  - Marek Jutel
PY  - 2020
JO  - Allergy
DO  - 10.1111/all.14342
UR  - https://doi.org/10.1111/all.14342
ER  - 

APA

Gajdanowicz, P., Elst, D. V., Smolińska, S., Eljaszewicz, A., O'Mahony, L., Kettner, A., & Jutel, M. (2020). The frequency of CD4 + CD25 + FoxP3 + CD127 − cells in Bet v 1 contiguous overlapping peptide immunotherapy as a putative marker of efficacy. Allergy. https://doi.org/10.1111/all.14342

Source records